1. Home
  2. FRSX vs HUMAW Comparison

FRSX vs HUMAW Comparison

Compare FRSX & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foresight Autonomous Holdings Ltd.

FRSX

Foresight Autonomous Holdings Ltd.

HOLD

Current Price

$1.30

Market Cap

6.5M

Sector

Technology

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

HOLD

Current Price

$0.09

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRSX
HUMAW
Founded
N/A
2004
Country
Israel
United States
Employees
N/A
220
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
N/A
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
FRSX
HUMAW
Price
$1.30
$0.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
615.0K
14.2K
Earning Date
03-24-2026
03-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$452,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$1.18
52 Week High
$13.22
$1.34

Technical Indicators

Market Signals
Indicator
FRSX
HUMAW
Relative Strength Index (RSI) 22.47 39.50
Support Level $1.31 $0.09
Resistance Level $1.74 $0.12
Average True Range (ATR) 0.10 0.03
MACD -0.03 0.00
Stochastic Oscillator 0.00 16.99

Price Performance

Historical Comparison
FRSX
HUMAW

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: